Replies to post #1661 on Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

Madrigal and Viking Therapeutics will be good for NASH fibrosis. We don't know how CNAT will play out in NASH fibrosis because the phase 2 ENCORE-NF trial won't read out until early 2019. But what we do know is that after only 3 months of treatment those with liver cirrhosis improved their condition (MELD) score compared to placebo. Conatus is king when it comes to more advanced NASH (NASH cirrhossis) so it should be good in the long run regardless. The phase 2b POLT-HCV-SVR trial is set to be read out Q2 2018 that will show if emricasan has a reversal of halt effect on fibrosis of the liver. It will be a nice early look. With good results in that trial, I expect the ENCORE-NF trial to do well as well.